Back to search

University of British Columbia

CRISPR-mediated upregulation of progranulin as a therapeutic modality for progranulin-deficient frontotemporal dementia

Abstract

dc:description

Frontotemporal dementia (FTD) is the second most common form of early-onset dementia and is a neurodegenerative disease with hallmark clinical deficits in executive function, social cognition and language processing. Heterozygous loss-of-function mutations in the progranulin gene (GRN) induce haploinsufficiency of progranulin (PGRN) and are identified as the major genetic cause of the tau-negative, ubiquitin-positive subtype of FTD. Progranulin’s contribution to the pathogenesis of FTD is associated with its role in lysosomal function, neuronal survival, and neuroinflammation. How PGRN haploinsufficiency causes neurodegeneration has been an active area of investigation, and boosting or restoring progranulin expression is a rational treatment strategy. In the current study, we proposed to increase the expression of the functional copy of the GRN to the wildtype level through Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based activation, using an AAV vector as the delivery platform. We used human-induced pluripotent stem cell (hiPSC)-derived cortical neurons bearing the heterozygous pathogenic GRN nonsense mutations (R418X and S116X) to evaluate the in vitro effect of the proposed CRISPRa treatment. We first characterized the R418X and S116X hiPSC cell lines, confirming reduced PGRN levels in these lines compared to wildtype. We also perform Bulk RNA sequencing to characterize hiPSC-derived neurons at the transcriptomic level. One-time transduction of the CRISPRa constructs successfully elevated the progranulin mRNA expression and increased progranulin protein levels in the GRN mutants. We next assessed whether our CRISPRa approach could increase brain progranulin levels in vivo, using a heterozygous Grn R493X mouse model administering the CRISPRa construct through a single retro-orbital injection. We confirmed that this approach, using the selected AAV serotype (AAV2/PHP.eB) in combination with the human synapsin promoter, led to robust and diffuse brain expression. However, administration of our CRISPRa construct did not increase progranulin expression in GrnR493X mice. Together, our findings suggest that activation of the normal allele in GRN haploinsufficiency through a CRISPRa approach can increase PGRN in hiPSC-derived neurons, but further work is required to fully determine optimal dose and delivery in vivo. Our novel findings add to a growing number of genetic approaches for treating FTD due to GRN haploinsufficiency.

Degree

thesis:*
Name thesis:degree_name
Master of Science - MSc
Level thesis:degree_level
master's
Discipline thesis:degree_discipline
Neuroscience
Grantor dc:publisher
University of British Columbia
Year dc:date
2024

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Cai, Wenji
Contributors dc:contributor
  • Nygaard, Haakon B.

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/89461

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Cai, Wenji. CRISPR-mediated upregulation of progranulin as a therapeutic modality for progranulin-deficient frontotemporal dementia. master's thesis, University of British Columbia, 2024. http://hdl.handle.net/2429/89461